Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human (FIH), Multicenter, Open-label Trial of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma (ACC) and Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07189403 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT07189403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07189403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human (FIH), Multicenter, Open-label Trial of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma (ACC) and Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Recruiting
Start date
November 4, 2025
Completion date
March 1, 2028
Enrollment
40 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic adrenocortical carcinoma, metastatic castration-resistant prostate cancer